AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28060600 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypercaloric refeeding with low-GI diet
Number of subjects: 15
Study 28060600 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypercaloric refeeding with high-GI diet
Number of subjects: 15
Study 28060600 — intervention group
Group type: EXPERIMENTAL
Intervention: Overfeeding (OF)
Number of subjects: 15
Study 28060600 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric restriction (CR)
Number of subjects: 15
Study 28060600 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypercaloric refeeding (RF)
Number of subjects: 15
Study 28060738 — intervention group
Group type: EXPERIMENTAL
Intervention: High level of ctDNA
Number of subjects: 34
Study 28061430 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin detemir (once-daily)
Number of subjects: 17374
Study 28061430 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 17374
Study 28061905 — intervention group
Group type: EXPERIMENTAL
Intervention: M. perstans infection assessment
Number of subjects: 2247
Study 28061905 — intervention group
Group type: EXPERIMENTAL
Intervention: Culicoides species assessment using CDC light traps and Human Landing Catch (HLC) method
Number of subjects: 2247
Study 28061905 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation assessment between Culicoides spp. and M. perstans prevalence
Number of subjects: 2247
Study 28062312 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic pancreatitis (CP) group
Number of subjects: 1301
Study 28062312 — intervention group
Group type: COMPARATOR
Intervention: Biliary diseases (BD) group
Number of subjects: 1301
Study 28062389 — intervention group
Group type: EXPERIMENTAL
Intervention: Keep It Up! (KIU!) intervention, which includes modules with videos, animation, games, and interactive exercises.
Number of subjects: 901
Study 28062389 — intervention group
Group type: COMPARATOR
Intervention: Control condition reflecting readily available HIV information on websites.
Number of subjects: 901
Study 28062631 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithms that included cardiac troponin (cTn) and glucose
Number of subjects: 1137
Study 28062631 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithms incorporating glucose with cTn
Number of subjects: 1137
Study 28062631 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithms for MI/cardiovascular death
Number of subjects: 1137
Study 28062705 — intervention group
Group type: EXPERIMENTAL
Intervention: PAK4 allosteric modulators (PAMs) including KPT-7523, KPT-7189, KPT-8752, KPT-9307, and KPT-9274
Number of subjects: 0
Study 28062705 — intervention group
Group type: EXPERIMENTAL
Intervention: KPT-9274
Number of subjects: 0
Study 28063459 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin enzyme converting inhibitors (86% of patients)
Number of subjects: 121
Study 28063459 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers (84% of patients)
Number of subjects: 121
Study 28063459 — intervention group
Group type: EXPERIMENTAL
Intervention: LV remodeling assessment (increase in end-diastolic volume (EDV) and/or ejection fraction (EF))
Number of subjects: 121
Study 28063459 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase-contrast Cardiovascular Magnetic Resonance (CMR)
Number of subjects: 121
Study 28063717 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lipid emulsions (LE)
Number of subjects: 45
Study 28064152 — intervention group
Group type: EXPERIMENTAL
Intervention: Left atrial expansion index
Number of subjects: 733
Study 28064152 — intervention group
Group type: COMPARATOR
Intervention: Lowest quartile of LA expansion index
Number of subjects: 733
Study 28064152 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal function decline
Number of subjects: 733
Study 28065165 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration therapy
Number of subjects: 19
Study 28065396 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS) at 0 to 200 μg
Number of subjects: 121
Study 28065396 — intervention group
Group type: COMPARATOR
Intervention: Inhaled corticosteroids (ICS) at 200 to 800 μg
Number of subjects: 121
Study 28065396 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS) at 200 μg
Number of subjects: 121
Study 28065396 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS) at 800 μg
Number of subjects: 121
Study 28065396 — intervention group
Group type: COMPARATOR
Intervention: ICS free
Number of subjects: 121
Study 28065396 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dose ramps of ICS
Number of subjects: 121
Study 28065396 — intervention group
Group type: EXPERIMENTAL
Intervention: All 3 dose ramps of ICS
Number of subjects: 121
Study 28065408 — intervention group
Group type: EXPERIMENTAL
Intervention: Short luteal phase (≤11 days)
Number of subjects: 284
Study 28065465 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib plus metformin
Number of subjects: 200
Study 28065465 — intervention group
Group type: COMPARATOR
Intervention: Gefitinib plus placebo
Number of subjects: 200
Study 28065678 — intervention group
Group type: EXPERIMENTAL
Intervention: PADQOL-16 instrument
Number of subjects: 0
Study 28065708 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-generation BAT system
Number of subjects: 30
Study 28065708 — intervention group
Group type: EXPERIMENTAL
Intervention: First-generation BAT system (active therapy)
Number of subjects: 30
Study 28065708 — intervention group
Group type: COMPARATOR
Intervention: First-generation BAT system (sham control)
Number of subjects: 30
Study 28065734 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass
Number of subjects: 100
Study 28065734 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 100
Study 28065734 — intervention group
Group type: COMPARATOR
Intervention: Roux-en-Y gastric bypass in adults
Number of subjects: 100
Study 28065736 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass
Number of subjects: 58
Study 28066274 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 sessions standardized pain-focused EMDR in addition to treatment-as-usual (TAU)
Number of subjects: 40
Study 28066274 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU) alone
Number of subjects: 40
Study 28067703 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia with halothane; 65% received regional or local anesthesia (caudal block in 79.23% or nerve block in 20.77%); average duration of surgery 33 ± 17.47 minutes.
Number of subjects: 103
Study 28067703 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory surgery program
Number of subjects: 103
Study 28067743 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic-assisted sacrocolpopexy (RSC)
Number of subjects: 78
Study 28067743 — intervention group
Group type: COMPARATOR
Intervention: Uterosacral ligament suspension (USLS)
Number of subjects: 78
Study 28068212 — intervention group
Group type: EXPERIMENTAL
Intervention: HZ/su vaccine (2 doses, 2 months apart)
Number of subjects: 96
Study 28068460 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant treatment for 12 weeks
Number of subjects: 808
Study 28068465 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar disorder with psychotropic exposure (BD+)
Number of subjects: 197
Study 28068465 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar disorder without psychotropic treatment (BD-)
Number of subjects: 197
Study 28068465 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonexposed infants)
Number of subjects: 197
Study 28068480 — intervention group
Group type: EXPERIMENTAL
Intervention: NeoCart implant
Number of subjects: 29
Study 28068564 — intervention group
Group type: EXPERIMENTAL
Intervention: PCA patients underwent positron emission tomography (PET) to measure translocator protein binding.
Number of subjects: 37
Study 28068564 — intervention group
Group type: EXPERIMENTAL
Intervention: Amnestic AD patients underwent positron emission tomography (PET) to measure translocator protein binding.
Number of subjects: 37
Study 28068564 — intervention group
Group type: COMPARATOR
Intervention: Age-matched controls underwent positron emission tomography (PET) to measure translocator protein binding.
Number of subjects: 37
Study 28068779 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine, up to 300 mg/day for approximately 12 weeks
Number of subjects: 350
Study 28068899 — intervention group
Group type: EXPERIMENTAL
Intervention: Salivary DNA methylation analysis using Infinium Illumina HumanMethylation 450 K BeadChip
Number of subjects: 92
Study 28068899 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathway analysis of methylation sites
Number of subjects: 92
Study 28068899 — intervention group
Group type: EXPERIMENTAL
Intervention: Identification of specific genes
Number of subjects: 92
Study 28068935 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer support intervention
Number of subjects: 75
Study 28069006 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-week multi-component family meals intervention (Simple Suppers)
Number of subjects: 60
Study 28069006 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 60
Study 28069017 — intervention group
Group type: EXPERIMENTAL
Intervention: CyberKnife SBRT at doses of 7 Gy, 7.5 Gy, 8 Gy, 8.5 Gy, 9 Gy, 9.5 Gy x 5
Number of subjects: 3
Study 28069016 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month individualized need-supportive physical activity counseling intervention
Number of subjects: 300
Study 28069016 — intervention group
Group type: COMPARATOR
Intervention: Reference group (no individualized PA counseling)
Number of subjects: 300
Study 28069358 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumococcal polysaccharide vaccine (PPSV) administered within 10 days after neurotrauma or neurosurgery
Number of subjects: 56
Study 28069358 — intervention group
Group type: COMPARATOR
Intervention: Pneumococcal polysaccharide vaccine (PPSV) administered after ≥3 weeks post neurotrauma or neurosurgery (control group)
Number of subjects: 56
Study 28069476 — intervention group
Group type: EXPERIMENTAL
Intervention: Behind-folds visualizing colonoscopy (Third Eye Retroscope, FUSE, EndoRings)
Number of subjects: 650
Study 28069476 — intervention group
Group type: COMPARATOR
Intervention: Standard colonoscopy
Number of subjects: 650
Study 28069574 — intervention group
Group type: EXPERIMENTAL
Intervention: Left Ventricular Hypertrophy (LVH)
Number of subjects: 764
Study 28069574 — intervention group
Group type: COMPARATOR
Intervention: Control (no LVH)
Number of subjects: 764
Study 28069624 — intervention group
Group type: EXPERIMENTAL
Intervention: Original Revised Cardiac Risk Index (RCRI)
Number of subjects: 34000
Study 28069624 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Revised Cardiac Risk Index (RCRI) incorporating CKD-Epi
Number of subjects: 34000
Study 28069838 — intervention group
Group type: EXPERIMENTAL
Intervention: Insertable cardiac monitors (ICM)
Number of subjects: 50
Study 28070266 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with autism
Number of subjects: 104
Study 28070266 — intervention group
Group type: COMPARATOR
Intervention: Typically developing controls
Number of subjects: 104
Study 28070710 — intervention group
Group type: EXPERIMENTAL
Intervention: Micro-injected vitrified/warmed oocytes
Number of subjects: 69
Study 28070710 — intervention group
Group type: COMPARATOR
Intervention: Micro-injected fresh oocytes
Number of subjects: 69
Study 28070710 — intervention group
Group type: EXPERIMENTAL
Intervention: Euploid blastocysts from vitrified/warmed oocytes
Number of subjects: 69
Study 28070710 — intervention group
Group type: COMPARATOR
Intervention: Euploid blastocysts from fresh oocytes
Number of subjects: 69
Study 28070715 — intervention group
Group type: EXPERIMENTAL
Intervention: Elotuzumab in combination with lenalidomide/dexamethasone or bortezomib/dexamethasone
Number of subjects: 390
Study 28070715 — intervention group
Group type: EXPERIMENTAL
Intervention: Elotuzumab monotherapy
Number of subjects: 390
Study 28070715 — intervention group
Group type: EXPERIMENTAL
Intervention: Elotuzumab
Number of subjects: 390
Study 28070718 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-06263507 at 0.05 to 6.5 mg/kg
Number of subjects: 26
Study 28070720 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD4547 (40 mg bid to 120 mg bid; 160 mg qd in Part A; 80 mg bid in Part B)
Number of subjects: 34
Study 28070720 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD4547
Number of subjects: 34
Study 28070941 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole/Omeprozole
Number of subjects: 1004
Study 28070941 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1004
Study 28070941 — intervention group
Group type: EXPERIMENTAL
Intervention: ASA grade IV classification
Number of subjects: 1004
Study 28072473 — intervention group
Group type: EXPERIMENTAL
Intervention: Obinutuzumab 1000 mg i.v. on Days 1, 8, and 15 of Cycle 1 (first infusion split over 2 days for CLL patients) and on Day 1 of Cycles 2-8 (21 days per cycle).
Number of subjects: 48
Study 28072473 — intervention group
Group type: EXPERIMENTAL
Intervention: Obinutuzumab exposure in CLL, DLBCL, and FL patients.
Number of subjects: 48
Study 28072811 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-entity hydrocodone (Hysingla® ER)
Number of subjects: 1207
Study 28072811 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1207
Study 28073613 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal allergen challenge in allergic rhinitis
Number of subjects: 0
Study 28073769 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalcetrapib
Number of subjects: 4073
Study 28073769 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4073
Study 28073822 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnoea (OSA) in EDS patients
Number of subjects: 100
Study 28073822 — intervention group
Group type: EXPERIMENTAL
Intervention: Excessive daytime sleepiness measured by the Epworth Sleepiness Scale in EDS patients
Number of subjects: 100
Study 28073822 — intervention group
Group type: COMPARATOR
Intervention: Matched control group (healthy adults)
Number of subjects: 100
Study 28073849 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver understands the severity of the illness and options available to the patient
Number of subjects: 96
Study 28073849 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver has identified a backup plan
Number of subjects: 96
Study 28073849 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver is able to provide logistical support
Number of subjects: 96
Study 28073849 — intervention group
Group type: EXPERIMENTAL
Intervention: At least 1 adult child who lives within 50 miles
Number of subjects: 96
Study 28073849 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended family who can care for the patient
Number of subjects: 96
Study 28073849 — intervention group
Group type: COMPARATOR
Intervention: Living alone
Number of subjects: 96
Study 28073849 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver characteristics
Number of subjects: 96
Study 28073993 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily goal establishment of mechanical ventilation (Phase I)
Number of subjects: 197
Study 28073993 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based data visualization system (T3) for daily goals of mechanical ventilation (Phase II)
Number of subjects: 197
Study 28073993 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined interventions (Daily goal formation and T3)
Number of subjects: 197
Study 28074137 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle diameter
Number of subjects: 30
Study 28074137 — intervention group
Group type: EXPERIMENTAL
Intervention: Lack of needle lubrication and small 'needle hooks'
Number of subjects: 30
Study 28074137 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-tip, obtuse needle grinds
Number of subjects: 30
Study 28074137 — intervention group
Group type: EXPERIMENTAL
Intervention: PF in skin and in polyurethane rubber
Number of subjects: 30
Study 28074137 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain outcome
Number of subjects: 30
Study 28074139 — intervention group
Group type: EXPERIMENTAL
Intervention: Egg inclusion (two eggs/day)
Number of subjects: 34
Study 28074154 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound in Rheumatoid Arthritis 9 joint/tendon score (USRA9) inflammation score
Number of subjects: 330
Study 28074154 — intervention group
Group type: COMPARATOR
Intervention: Formerly proposed scores
Number of subjects: 330
Study 28076240 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 1982
Study 28076247 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin 750 mg intravenously/by mouth once daily for 5 days
Number of subjects: 224
Study 28076247 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin 400/500 mg intravenously/by mouth twice daily for 10 days
Number of subjects: 224
Study 28076352 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT (eight 1 min bouts of cycling at 85% maximal workload (Wmax) with 1 min of active recovery between bouts)
Number of subjects: 12
Study 28076352 — intervention group
Group type: COMPARATOR
Intervention: MICT (20 min of cycling at 45% Wmax)
Number of subjects: 12
Study 28076352 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT
Number of subjects: 12
Study 28076352 — intervention group
Group type: COMPARATOR
Intervention: MICT
Number of subjects: 12
Study 28076966 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus once daily + sorafenib twice daily (continuous schedule)
Number of subjects: 26
Study 28076966 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus continuous and sorafenib 3 days on/4 days off (intermittent schedule)
Number of subjects: 26
Study 28077098 — intervention group
Group type: EXPERIMENTAL
Intervention: Last menstrual period
Number of subjects: 912
Study 28077098 — intervention group
Group type: EXPERIMENTAL
Intervention: Farr examination
Number of subjects: 912
Study 28077098 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound
Number of subjects: 912
Study 28077369 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-2 visual fields (VFs)
Number of subjects: 125
Study 28077376 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intake
Number of subjects: 0
Study 28077380 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 28077381 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary α-tocopherol supplementation
Number of subjects: 0
Study 28077381 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 0
Study 28077384 — intervention group
Group type: EXPERIMENTAL
Intervention: High-potency statin (≥40 mg atorvastatin, ≥20 mg rosuvastatin, or 80 mg simvastatin daily)
Number of subjects: 12446
Study 28077384 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin use (not specified if high-potency or not)
Number of subjects: 12446
Study 28077384 — intervention group
Group type: COMPARATOR
Intervention: Age ≥75 years
Number of subjects: 12446
Study 28077384 — intervention group
Group type: COMPARATOR
Intervention: Female sex
Number of subjects: 12446
Study 28077384 — intervention group
Group type: COMPARATOR
Intervention: Renal dysfunction
Number of subjects: 12446
Study 28077384 — intervention group
Group type: COMPARATOR
Intervention: Heart failure during hospital admission
Number of subjects: 12446
Study 28077384 — intervention group
Group type: COMPARATOR
Intervention: Low-density lipoprotein cholesterol <70 mg/dL at 3 months
Number of subjects: 12446
Study 28077384 — intervention group
Group type: COMPARATOR
Intervention: Lower low-density lipoprotein cholesterol
Number of subjects: 12446
Study 28077459 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Office Visit
Number of subjects: 0
Study 28077536 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting position during neurosurgery
Number of subjects: 35
Study 28077859 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration training (WBVT)
Number of subjects: 38
Study 28078066 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifelong high-level recreational activity
Number of subjects: 0
Study 28078107 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab added to induction chemotherapy and concurrent chemoradiation with cisplatin/irinotecan
Number of subjects: 33
Study 28078162 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole IR
Number of subjects: 0
Study 28078162 — intervention group
Group type: COMPARATOR
Intervention: Ropinirole IR
Number of subjects: 0
Study 28078634 — intervention group
Group type: EXPERIMENTAL
Intervention: Natalizumab
Number of subjects: 94
Study 28078634 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 28078669 — intervention group
Group type: EXPERIMENTAL
Intervention: PUVA maintenance phase
Number of subjects: 1
Study 28078669 — intervention group
Group type: COMPARATOR
Intervention: Follow-up (no PUVA maintenance)
Number of subjects: 1
Study 28078750 — intervention group
Group type: EXPERIMENTAL
Intervention: Prebiotic (2.8 g/day HOST-G904)
Number of subjects: 20
Study 28079588 — intervention group
Group type: EXPERIMENTAL
Intervention: Cricoid pressure (CP) applied with a median force of 30.8 N in men (95% CI = 28.15-33.5)
Number of subjects: 60
Study 28079588 — intervention group
Group type: EXPERIMENTAL
Intervention: Cricoid pressure (CP) applied with a median force of 18.7 N in women (95% CI = 17.1-20.3)
Number of subjects: 60
Study 28079588 — intervention group
Group type: COMPARATOR
Intervention: Comparison of cricoid forces between genders
Number of subjects: 60
Study 28079702 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomic analysis with random survival forests (RSFs)
Number of subjects: 66
Study 28079870 — intervention group
Group type: EXPERIMENTAL
Intervention: l-carnitine supplementation added to parenteral nutrition in 390 (39%) study subjects
Number of subjects: 995
Study 28079870 — intervention group
Group type: COMPARATOR
Intervention: Non-supplemented infants (592 subjects)
Number of subjects: 995
Study 28079870 — intervention group
Group type: EXPERIMENTAL
Intervention: l-carnitine supplementation
Number of subjects: 995
Study 28081133 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled human malaria infection (CHMI)
Number of subjects: 57
Study 28081133 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothetical malaria vaccine trials
Number of subjects: 57
Study 28081133 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatic vaccine trials
Number of subjects: 57
Study 28081133 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle-injected CHMI
Number of subjects: 57